Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Significance of Uracil/Tegafur for Preventing Intravesical Recurrence of Non-Muscle Invasive Urothelial Carcinoma of the Bladder

Significance of Uracil/Tegafur for Preventing Intravesical Recurrence of Non-Muscle Invasive... Background: The objective of this study was to assess the role of uracil/tegafur (UFT) and its metabolite γ-butyrolactone (GBL), a potent inhibitor of angiogenesis, in the prevention of intravesical recurrence in patients with non-muscle invasive urothelial carcinoma of the bladder (NMIUCB). Patients and Methods: This study included 48 patients with NMIUCB following complete transurethral resection who were randomly divided into 27 receiving UFT therapy (group A) and 21 without any adjuvant therapies (group B). Serum levels of GBL, vascular endothelial growth factor, basic fibroblast growth factor, platelet-derived growth factor and interleukin-8 were measured. Results: There was no significant difference in the intravesical recurrence-free survival between groups A and B. Despite the lack of significant differences in serum levels of vascular endothelial growth factor, basic fibroblast growth factor, platelet-derived growth factor and interleukin-8, serum GBL in group A was significantly greater than in group B. Multivariate analysis identified tumor size as an independent predictor of intravesical recurrence irrespective of the other factors examined. Conclusions: Despite the significant induction of GBL, adjuvant UFT therapy failed to show a preventive effect on intravesical recurrence of NMIUCB. Therefore, we should consider enhancing the anti-angiogenic effect of GBL using an alternative administration schedule of UFT. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Urology Karger

Significance of Uracil/Tegafur for Preventing Intravesical Recurrence of Non-Muscle Invasive Urothelial Carcinoma of the Bladder

Loading next page...
 
/lp/karger/significance-of-uracil-tegafur-for-preventing-intravesical-recurrence-9vVOZPEq95
Publisher
Karger
Copyright
© 2012 S. Karger AG, Basel
ISSN
1661-7649
eISSN
1661-7657
DOI
10.1159/000338866
Publisher site
See Article on Publisher Site

Abstract

Background: The objective of this study was to assess the role of uracil/tegafur (UFT) and its metabolite γ-butyrolactone (GBL), a potent inhibitor of angiogenesis, in the prevention of intravesical recurrence in patients with non-muscle invasive urothelial carcinoma of the bladder (NMIUCB). Patients and Methods: This study included 48 patients with NMIUCB following complete transurethral resection who were randomly divided into 27 receiving UFT therapy (group A) and 21 without any adjuvant therapies (group B). Serum levels of GBL, vascular endothelial growth factor, basic fibroblast growth factor, platelet-derived growth factor and interleukin-8 were measured. Results: There was no significant difference in the intravesical recurrence-free survival between groups A and B. Despite the lack of significant differences in serum levels of vascular endothelial growth factor, basic fibroblast growth factor, platelet-derived growth factor and interleukin-8, serum GBL in group A was significantly greater than in group B. Multivariate analysis identified tumor size as an independent predictor of intravesical recurrence irrespective of the other factors examined. Conclusions: Despite the significant induction of GBL, adjuvant UFT therapy failed to show a preventive effect on intravesical recurrence of NMIUCB. Therefore, we should consider enhancing the anti-angiogenic effect of GBL using an alternative administration schedule of UFT.

Journal

Current UrologyKarger

Published: Jan 1, 2012

Keywords: Non-muscle invasive urothelial carcinoma of the bladder; Uracil/tegafur; Recurrence; Angiogenesis; γ-butyrolactone

There are no references for this article.